ATE393170T1 - Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers - Google Patents

Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers

Info

Publication number
ATE393170T1
ATE393170T1 AT02743765T AT02743765T ATE393170T1 AT E393170 T1 ATE393170 T1 AT E393170T1 AT 02743765 T AT02743765 T AT 02743765T AT 02743765 T AT02743765 T AT 02743765T AT E393170 T1 ATE393170 T1 AT E393170T1
Authority
AT
Austria
Prior art keywords
antibody
fragment
growth factor
fibroblast growth
antibody against
Prior art date
Application number
AT02743765T
Other languages
English (en)
Inventor
Kenya Shitara
Kazuyasu Nakamura
Maiko Hirota
Naoki Shimada
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE393170T1 publication Critical patent/ATE393170T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02743765T 2001-06-28 2002-06-28 Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers ATE393170T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001196176 2001-06-28

Publications (1)

Publication Number Publication Date
ATE393170T1 true ATE393170T1 (de) 2008-05-15

Family

ID=19034030

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02743765T ATE393170T1 (de) 2001-06-28 2002-06-28 Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers

Country Status (9)

Country Link
US (1) US7939077B2 (de)
EP (1) EP1422243B1 (de)
JP (1) JP4152315B2 (de)
AT (1) ATE393170T1 (de)
AU (1) AU2002346127B2 (de)
CA (1) CA2451854A1 (de)
DE (1) DE60226253T2 (de)
ES (1) ES2303859T3 (de)
WO (1) WO2003002608A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241568B2 (en) 1996-04-03 2007-07-10 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
AU2002361106B2 (en) * 2001-12-28 2007-06-07 Kyowa Hakko Kirin Co., Ltd. Remedies for arthritis
EP1606387A4 (de) * 2003-03-04 2008-04-23 Alexion Pharma Inc Zur erzeugung konstanter hybridbereiche verwendete vektoren
WO2006121159A1 (ja) * 2005-05-12 2006-11-16 Kyowa Hakko Kogyo Co., Ltd. Cd10に特異的に反応するヒト型cdr移植抗体およびその抗体断片
WO2007142277A1 (ja) 2006-06-06 2007-12-13 Kyowa Hakko Kirin Co., Ltd. ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体
JP5532401B2 (ja) 2007-12-05 2014-06-25 協和発酵キリン株式会社 ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2156949B1 (de) 2008-08-19 2014-11-19 Cryovac, Inc. Für Vakuumhautverpackungsanwendungen geeigneter Film und damit hergestelltes einfach zu öffnendes Vakuumhautpaket

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE216592T1 (de) * 1991-01-17 2002-05-15 Univ Washington Anti-plättchen-wachstumsfaktor-antikörper in der behandlung von restenose
JP3708210B2 (ja) 1996-04-03 2005-10-19 協和醗酵工業株式会社 抗線維芽細胞増殖因子−８モノクローナル抗体
JP4550947B2 (ja) * 1997-03-19 2010-09-22 協和発酵キリン株式会社 ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体
JP2001046066A (ja) * 1999-08-03 2001-02-20 Kyowa Hakko Kogyo Co Ltd 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体

Also Published As

Publication number Publication date
US20040253234A1 (en) 2004-12-16
DE60226253T2 (de) 2009-05-14
ES2303859T3 (es) 2008-09-01
EP1422243A4 (de) 2005-05-04
AU2002346127B2 (en) 2008-05-29
DE60226253D1 (de) 2008-06-05
EP1422243A1 (de) 2004-05-26
US7939077B2 (en) 2011-05-10
CA2451854A1 (en) 2003-01-09
WO2003002608A1 (fr) 2003-01-09
JPWO2003002608A1 (ja) 2004-10-14
JP4152315B2 (ja) 2008-09-17
EP1422243B1 (de) 2008-04-23

Similar Documents

Publication Publication Date Title
HK1078613A1 (zh) 通过抗-erbb2抗体医治非恶性疾病或病患的疗法
DE60236646D1 (de) Anti-VEGF-2 Antikörper
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE482234T1 (de) Antikörper gegen kdr, deren herstellung und verwendungen
DK1218509T3 (da) Fibroblast vækstfaktorlignende polypeptider
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
ATE439381T1 (de) Reinigung von polyreaktiven autoantikörpern und deren verwendungen
DE60226253D1 (de) Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers
BR0308606A (pt) Derivados de hemiasterlina e usos destes
AU2003263712A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
AU2002326285A1 (en) Method for treating psoriasis by using an il-17d antagonist
WO2003048317A3 (en) Antibodies to magmas and uses thereof
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
BRPI0415355A (pt) triarilimidazóis
ITGE20020050A0 (it) Procedimento per il trattamento di filati mediante agugliatura.
WO2003037257A3 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
WO2002044366A3 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
WO2002007740A3 (de) Schlangentoxin und dessen verwendung als arzneimittel
EP1566386A4 (de) Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür
NO20033401L (no) Kjemiske forbindelser
MXPA03010739A (es) Moleculas de marcador endotelial tumoral 7-alfa y uso de las mismas.
WO2001094530A3 (fr) Nouveau polypeptide, proteine 57 de la sous-famille des proteines a doigt de zinc scan, et polynucleotide codant ce polypeptide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties